We’ve developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities

Our goal is to transform cancer treatment options for patients by developing ALX148 as a foundational checkpoint immunotherapy

ALX Oncology was founded by a team of industry veterans to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target.

Cancer cells employ CD47, a cell surface protein, as a “don’t eat me” signal to evade detection by the immune system. ALX is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, ALX148, will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability, our strategy is to pursue ALX148 as a potentially critical component for future combination treatments in oncology.

Latest News updated at 21:23:06 UTC

Sep 22, 2020

ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head & Neck Cancer

Sep 17, 2020

ALX Oncology Added to Russell 2000® and 3000® Indexes

Sep 08, 2020

ALX Oncology Announces Participation at Upcoming Investor Conferences


ALX Oncology Pairs Lead Asset with Keytruda in HNSCC Study | BioSpace https://www.biospace.com/article/alx-oncology-collaborates-with-merck-in-hnscc-study/?TrackID=16 #Keytruda #Merck #ALXOncology

ALX Oncology is excited to announce a collaboration with @Merck on Phase 2 immuno-oncology studies evaluating ALX148, targeting #CD47, in combination with KEYTRUDA® in patients with head & neck cancer: https://bit.ly/3iRuly8

ALX Oncology will be added as a member of the Russell 2000® and 3000® Indexes, effective after the U.S. market opens tomorrow, September 18, 2020: https://bit.ly/35Jf12I

Load More...

Our Technology

ALX Oncology’s fusion proteins are engineered to bind CD47 with significantly greater affinity than natural SIRPα. Our lead candidate, ALX148, is an intravenously administered fusion protein containing two engineered high affinity CD47 binding domains of SIRPα linked to an inactive Fc region of human immunoglobulin.